바카라 배팅 법 releases 52-week Phase 3 trial results of EYDENZELT for eye disease in international academic journal

[by Kang, In Hyo] 바카라 배팅 법 announced on September 3 that the 52-week findings from its global Phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT (development code name CT-P42), were published in the international journal Ophthalmology and Therapy.

바카라 배팅 법 is a biosimilar of EYLEA (aflibercept), a blockbuster ophthalmic treatment that generated global sales of USD 9.523 billion (approximately KRW 13.3322 trillion) last year.

The findings announced today comprise the 52-week long-term data from Celltrion’s global Phase 3 clinical trial involving 348 patients with diabetic macular edema (DME). The study compared the therapeutic equivalence, sustained efficacy, and safety of EYDENZELT in comparison with the reference product (EYLEA).

The study findings indicated that both treatment groups exhibited progressive improvement in best-corrected visual acuity (BCVA) from baseline by week 16, with stable levels maintained through week 52, thereby confirming the long-term therapeutic efficacy of 바카라 배팅 법. In addition, no significant differences were observed between the two groups with respect to secondary efficacy endpoints, such as average change in central retinal thickness, nor in overall safety outcomes.

Before this announcement, 바카라 배팅 법 had presented the results of its global Phase 3 clinical trial of EYDENZELT at two internationally recognized ophthalmology conferences, the Association for Research in Vision and Ophthalmology (ARVO) and the European Society of Retina Specialists (EURETINA). With the ongoing recognition and publication of EYDENZELT's efficacy and safety data by leading academic societies and peer-reviewed journals, 바카라 배팅 법 expects to further strengthen physician preference and trust in prescribing the therapy.

On the basis of the global Phase 3 clinical trial results, the company has obtained regulatory approval in several major countries, including Korea, the European Commission (EC), and Australia. Furthermore, 바카라 배팅 법 intends to expedite commercialization in additional key countries where approval remains pending, with the goal of rapidly expanding its market share once approval is granted.

"The global clinical trial results of EYDENZELT have been recognized and published by prestigious global academic societies and journals, further reinforcing its long-term clinical foundation. As we continue to obtain regulatory approval in major global markets, we are fully committed to expediting the remaining commercialization process and ensuring a stable and timely supply of the product to the market," a Celltrion official stated.